Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Editas Medicine, Inc. (NASDAQ: EDIT).

Full DD Report for EDIT

You must become a subscriber to view this report.


Recent News from (NASDAQ: EDIT)

Long-Term Outlook For Editas Medicine: December 1, 2018
Editas Medicine ( EDIT ) is in the middle of a price recovery, following months of price retracement and consolidation. This is after the stock price of the genome editing company Editas Medicine Inc. posted a very strong start to 2018 on the back of its ground breaking genome editing research...
Source: SeekingAlpha
Date: December, 03 2018 05:41
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease ...
Source: GlobeNewswire
Date: December, 02 2018 19:35
Editas Medicine (EDIT) CEO Katrine Bosley on Q3 2018 Results - Earnings Call Transcript
Editas Medicine (EDIT) Q3 2018 Earnings Conference Call November 7, 2018 5:00 PM ET Executives Mark Mullikin - Senior Director of Finance and Investor Relations Katrine Bosley - Chief Executive Officer Andrew Hack - Chief Financial Officer Gerald Cox - Chief Medical Officer C...
Source: SeekingAlpha
Date: November, 07 2018 21:47
Editas Medicine beats by $0.35, beats on revenue
Editas Medicine (NASDAQ: EDIT ): Q3 GAAP EPS of -$0.32 beats by $0.35. More news on: Editas Medicine, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:19
Editas Medicine 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Editas Medicine in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:11
Editas Medicine Announces Third Quarter 2018 Results and Update
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight novel Sickle Cell Disease and Beta-Thalassemia program Strong balance sheet with $3...
Source: GlobeNewswire
Date: November, 07 2018 16:01
Notable earnings after Wednesday's close
AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...
Source: SeekingAlpha
Date: November, 06 2018 17:35
The Biotech Bumps
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
Source: SeekingAlpha
Date: November, 01 2018 08:00
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the third ...
Source: GlobeNewswire
Date: October, 31 2018 16:01
Sangamo: Did It Work?
Introduction: Twitter's darling Sangamo ( SGMO ) dropped data yesterday from their first-in-human gene editing trial of SB-913. SGMO rode a wave of expectations on their way to the readout, with shares trading up 35% in the previous month. The stock has since plummeted to below previous trad...
Source: SeekingAlpha
Date: September, 07 2018 17:59

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0829.9330.2530.8029.62462,121
2018-09-0632.0030.0132.4429.92612,630
2018-09-0532.4432.0032.4430.74842,009
2018-09-0433.1832.8033.3431.73701,864
2018-08-3132.0032.8333.1331.83769,498

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1247,37084,71555.9169Short
2018-12-1171,700118,74860.3800Short
2018-12-1049,26994,30552.2443Short
2018-12-0760,16795,19663.2033Short
2018-12-0685,509142,76159.8966Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EDIT.


About Editas Medicine, Inc. (NASDAQ: EDIT)

Logo for Editas Medicine, Inc. (NASDAQ: EDIT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,708,484,189 - 05/15/2018
  • Issue and Outstanding: 46,884,857 - 02/28/2018

 


Recent Filings from (NASDAQ: EDIT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 16 2018

 

 


Daily Technical Chart for (NASDAQ: EDIT)

Daily Technical Chart for (NASDAQ: EDIT)


Stay tuned for daily updates and more on (NASDAQ: EDIT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EDIT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EDIT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EDIT and does not buy, sell, or trade any shares of EDIT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/